Interleukin-10 reduces hyperalgesia and the level of Interleukin-1beta in BALB/c mice infected with Leishmania major with no major effect on the level of Interleukin-6.
Infection with a high dose of Leishmania major has been shown to induce hyperalgesia in BALB/c mice accompanied by a sustained upregulation of Interleukin-1beta (IL-1beta) and an early upregulation of Interleukin-6 (IL-6). On the other hand, Interleukin 10 (IL-10) has been demonstrated to be hypoalgesic in other models such as rats exposed to UV rays. In this study, we injected BALB/c mice with a high dose of Leishmania major and treated them with IL-10 (15 ng/animal) for six consecutive days. Hyperalgesia was assessed using thermal pain tests and the levels of IL-1beta and IL-6 were also assessed at different post-infection days. Our results show that IL-10 can reduce the Leishmania major-induced hyperalgesia during the treatment period through a direct effect on the levels of IL-1beta which seems to play an important role in this hyperalgesia induction since its level was reduced during the period of IL-10 injection and was increased again when this treatment was stopped. On the contrary IL-10 has no direct effect on the levels IL-6 which seems to have no direct role in the induced hyperalgesia.
Karam
Marc C
MC
Department of Biology, School of Arts and Sciences, Lebanese American University, Byblos, Lebanon. marckaram@terra.net.lb
Hamdan
Hamdan G
HG
Abi Chedid
Najib A
NA
Bodman-Smith
Kikki B
KB
Baroody
George M
GM
D000704:Analysis of Variance; D000818:Animals; D005260:Female; D006930:Hyperalgesia / Q000188:drug therapy* / Q000209:etiology; D016753:Interleukin-10 / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D018320:Leishmania major; D016773:Leishmaniasis, Cutaneous / Q000150:complications*; D051379:Mice; D008807:Mice, Inbred BALB C; D011930:Reaction Time / Q000187:drug effects
D053583:Interleukin-1beta; D015850:Interleukin-6; D016753:Interleukin-10